HLA Typing for Transplant Market Size By Technology (Non-Molecular Assays [Serological Assays, Mixed Lymphocyte Culture Assay], Molecular Assays [PCR Based Molecular Assays, Sequencing Based Molecular Assays {Sanger Sequencing, Next Generation Sequencing}

HLA Typing for Transplant Market Size By Technology (Non-Molecular Assays [Serological Assays, Mixed Lymphocyte Culture Assay], Molecular Assays [PCR Based Molecular Assays, Sequencing Based Molecular Assays {Sanger Sequencing, Next Generation Sequencing}]), By Product And Services (Instruments, Reagents And Consumables, Software, Services), By Application (Diagnostics, Research), By End-Use (Hospitals, Diagnostic Labs, Academic And Research Institutes), Industry Analysis Report, Industry Analysis Report, Regional Outlook Growth Potential, Competitive Market Share & Forecast, 2023-2032

HLA Typing for Transplant Market is speculated to record significant growth by 2032 fueled by technological developments in molecular assays. Companies are focusing on developing novel platforms for HLA typing that offer high accuracy levels and more reliability.

For instance, in May 2022, CareDx announced presenting its latest innovations in AlloSeq portfolio at European EFI 2022 Conference. The company put forth information on its pre- and post-Alloseq transplant solutions for human leukocyte antigen typing. These include QTYPE and post-transplant hematopoietic stem cell and organ transplant surveillance.

Furthermore, factors like rise in organ transplantation procedures and increasing prevalence of chronic disorder among geriatric population would support the market progression.

HLA typing for transplant market is bifurcated into technology, applications, products and services, end-use, and regional landscape.

In terms of products and services, the instrument segment was valued at USD 148 million in 2022 and is predicted to grow significantly between 2023-2032. HLA typing for transplant instruments are being developed with emphasis on cost effectiveness and function. Introduction to advanced technologies have expedited the development of instruments that deliver better and accurate results in less time.

Based on the application, HLA typing for transplant market from diagnostics segment would gain appreciable impetus through 2032. In 2022, the segment accounted for nearly USD 575 million remuneration. Growing awareness initiatives for organ donations by private, public institutions, and NGOs is estimated to enhance organ transplantation, generating lucrative opportunities for segmental expansion. In India, more than 60 NGOs resolved to launch a national campaign for organ donation nationwide.

Academic and research institutes are observing increased prominence across HLA typing for transplant market. HLA typing for research activities is preferred due to the introduction of instrument and technologies that allow scientists to perform assays. Various research projects are underway. For example, the International Center for Blood Marrow Transplant Research announced partnering with Medical College for Wisconsin and National Marrow Donor Program. The alliance is aimed at the advancement of HCT and cellular therapy to improve survival rate of patients and their quality of life.

Such programs and initiatives would foster the segmental growth over the coming years. Incidentally, the academic and research institute segment is poised to grow at more than 8% CAGR during 2023-2032.

Considering the regional point of view, Asia Pacific HLA typing for transplant market is foreseen to gain substantial traction through 2032. Surging demand for high-resolution HLA genotyping, adoption of advanced technologies for stem cell and organ donations, and rising government initiatives to support development of HLA typing for enhanced transplantation procedures would contribute to the regional market expansion.

Notable companies operating in HLA typing for transplant business are CareDx, Abbott Laboratories, GenDx, BioReference Laboratories, and Luminex Corporation, amongst others.